Business Brief
IBA teams with maker of novel PET agent
IBA teams with maker of novel PET agent
Ion Beam Applications and NeuroSurvival Technologies will work together to distribute, as well as optimize the radiochemistry of, NST's molecular imaging agent for apoptosis, the genetically controlled process of cell death associated with many diseases, including cancer. The agent, Aposense, will be distributed to sites participating in multicenter clinical trials to document whether the PET radiotracer incorporating fluorine-18 selectively targets and accumulates within cells undergoing apoptosis. IBA Molecular, a business unit of IBA, provides PET radiopharmaceuticals through a global network of radiopharmacies using 37 cyclotron-equipped manufacturing sites.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
